Abstract

The advent of antiretroviral therapy has transformed Human Immunodeficiency Virus infection from a fatal 
diagnosis into a manageable chronic condition, yet the virus persisted in latent reservoirs that remained untouched 
by current treatment strategies. Despite decades of viral suppression, patients cannot safely discontinue therapy 
without experiencing rapid viral rebound, underscoring the urgent need for curative interventions. This review 
examined the emerging role of toll-like receptor agonists as adjuvants in therapeutic HIV vaccines designed to 
reduce or eliminate viral reservoirs. This article synthesized current literature on TLR agonist based therapeutic 
vaccines, examining preclinical studies, clinical trial data, and immunological mechanisms underlying their potential 
efficacy. The findings revealed that TLR agonists, particularly those targeting TLR7, TLR8, and TLR9, 
demonstrated significant capacity to reverse viral latency, enhance HIV specific cytotoxic T lymphocyte responses, 
and promoted innate immune activation that collectively contributed to measurable reductions in reservoir size. 
Clinical trials had shown promising but variable results, with some patients achieving prolonged periods of viral 
control following analytical treatment interruption. The integration of TLR agonists into therapeutic vaccine 
platforms represented a scientifically rational approach to achieving functional HIV cure, though significant 
challenges regarding safety, efficacy, and patient selection remained. Future research should prioritize combination 
immunotherapeutic strategies that synergistically target multiple aspects of viral persistence.